Aarti Pharmalabs Limited (AARTIPHARM.NS) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-26). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from published company financials, balance sheet as of 2026-03-31. AARTIPHARM.NS files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 9.76% | 30.00% | Pass |
| Interest-bearing investments | 0.12% | 30.00% | Pass |
| Non-permissible income | 0.43% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 23.64% | 33.00% | Pass |
| Interest-bearing investments | 0.28% | 33.00% | Pass |
| Non-liquid assets | 82.97% | at least 20.00% | Pass |
| Non-permissible income | 0.43% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 21.67% | 33.33% | Pass |
| Cash + interest-bearing securities | 0.28% | 33.33% | Pass |
| Accounts receivable | 17.03% | 33.33% | Pass |
| Non-permissible income | 0.43% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 21.67% | 33.33% | Pass |
| Cash + interest-bearing securities | 0.28% | 33.33% | Pass |
| Accounts receivable | 17.03% | 50.00% | Pass |
| Non-permissible income | 0.43% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 10.99% | 33.00% | Pass |
| Cash + interest-bearing securities | 0.14% | 33.00% | Pass |
| Accounts receivable | 8.49% | 33.00% | Pass |
| Non-permissible income | 0.43% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 12.29% | 33.00% | Pass |
| Cash + interest-bearing securities | 0.16% | 49.00% | Pass |
| Accounts receivable | 9.50% | 49.00% | Pass |
| Non-permissible income | 0.43% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 12.29% | 33.33% | Pass |
| Cash + interest-bearing securities | 0.16% | 33.33% | Pass |
| Accounts receivable | 9.66% | 49.00% | Pass |
| Non-permissible income | 0.43% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 53.50 | NEUTRAL |
| Stochastic %K (14) | 29.60 | NEUTRAL |
| CCI (20) | -91.50 | NEUTRAL |
| Williams %R (14) | -70.40 | NEUTRAL |
| MACD (12,26,9) | -7.49 | SELL |
| ROC (10) | 2.37 | BUY |
| Momentum (10) | 19.25 | BUY |
| EMA (10) | 842.48 | SELL |
| SMA (10) | 850.06 | SELL |
| EMA (20) | 831.30 | BUY |
| SMA (20) | 844.84 | SELL |
| EMA (30) | 814.13 | BUY |
| SMA (30) | 815.33 | BUY |
| EMA (50) | 785.60 | BUY |
| SMA (50) | 767.29 | BUY |
| EMA (100) | 752.68 | BUY |
| SMA (100) | 728.68 | BUY |
| EMA (200) | 751.98 | BUY |
| SMA (200) | 722.23 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Drug Manufacturers - Specialty & Generic
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acid and allied products, including sulphuric acid, sulphur trioxide, oil, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is headquartered in Mumbai, India.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
